Study of CGT4255 for advanced solid tumors with HER2 changes
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an oral drug called CGT4255 for people with advanced solid tumors that have certain changes in the HER2 gene or related proteins. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed advanced solid tumor that has spread or cannot be removed by surgery.
- Your tumor must have a specific HER2 gene change, NRG1 fusion, or HER2 protein overexpression.
- Your cancer must be measurable on scans.
- You must be in good enough health to carry out daily activities (ECOG score 0-1 or 0-2 depending on the part).
- Your blood tests must be within acceptable ranges.
- You cannot have had certain cancer treatments or major surgeries within a few weeks before starting the study drug.
- You must not have significant heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (YH42946) in people with advanced solid tumors that have specific changes in HER2 or EGFR genes and have stopped responding to standard therapies. The drug aims to target these genetic changes to slow or shrink the cancer. Participants will be monitored closely for safety and how well the drug works.
This trial tests a new drug called BM230 for people with advanced solid tumors that have HER2 protein or gene changes. It aims to see if the drug is safe and effective for those who have run out of standard treatment options.
This study tests a new antibody-drug conjugate (FDA022-BB05) for people with advanced solid cancers—especially breast, endometrial, bladder, colorectal, or lung cancer—that have stopped responding to standard therapy. The drug targets HER2, a protein on some cancer cells, to try to shrink tumors or slow their growth.
This trial tests a new drug called SSGJ-612 for people with advanced solid tumors that have stopped responding to standard treatments. It is specifically for patients whose tumors have a protein called HER2, and it aims to see if the drug can shrink or control the cancer.
This early-phase trial tests a new oral drug (CSCJC3456) for people with advanced solid tumors, especially those with certain FGFR gene changes. It aims to see if the drug is safe and may help when other treatments have stopped working.
This trial tests a new drug called SYS6023 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if your tumor has a specific protein called HER3 or certain genetic changes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.